Link Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy

Link Kooperations- und Lizenzvereinbarung zwischen Takeda, Zedira und Dr. Falk Pharma zur Entwicklung einer First-in-Class-Therapie für die Zöliakie

Link Co-authored posters at ICDS 2022

Link Successful ISO9001:2015 recertification

Link Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of non-alcoholic fatty liver disease (NAFLD)

Link Zedira publication - Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease

Link Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease

Link Dr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease

Link Dr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie

Link Reversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis

Link DZG Aktuell: Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227

Link Design of Oral FXIIIa Blockers as Safer Anticoagulants Mission Impossible?

Link Microbial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering

Link Tridegin as FXIIIa inhibitor

Link Microbial transglutaminase: from discovery to market

Link Tissue transglutaminase inhibitors

Link Tissue transglutaminase in Alzheimers Disease

Link Factor XIIIa: novel target for anticoagulation?

Link Microbial transglutaminase for site-specific protein conjugation

Link Transglutaminases: current research and applications - future directions